Dolutegravir-a promising antiretroviral in development

The Lancet Infectious Diseases

Volumn 12, Issue 2, 2012, Pages 90-91

  Boyd, Mark ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CYTOCHROME P450; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; RALTEGRAVIR; TENOFOVIR;

DIET RESTRICTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; LETTER; PILL; PRIORITY JOURNAL; RNA VIRUS; VIRUS LOAD;

FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE;

EID: 84856221584     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70291-2     Document Type: Letter

References (11)

1. Correll PK, Law MG, McDonald AM, Cooper DA, Kaldor JM HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 1998, 169:469-472.
2. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293-299. Antiretroviral Therapy Cohort Collaboration.
3. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010, 24:1527-1535.
4. Carr A, Cooper DA Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423-1430.
5. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2011, published online Oct 21. 10.1016/S1473-3099(11)70290-0.
6. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806.
7. Gilead Press release: Gilead's investigational antiretroviral quad regimen meets 48-week primary objective in pivotal phase 3 clinical study 102 (accessed Oct 10, 2011). http://www.gilead.com/pr_1596378.
8. Eron JJ, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011, published online Sept 19. 10.1016/S1473-3099(11)70196-7.
9. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426. D:A:D Study Group.
10. Ding X, Andraca-Carrera E, Cooper C, et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011. Abstr 808.
11. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009, 361:2230-2240.